{"cluster": 45, "subcluster": 4, "abstract_summ": "Hospitalized COVID-19 patients should be placed on thromboprophylaxis with the option of full-therapeutic anticoagulation or tissue plasminogen activator (tPA) in high risk or mechanically ventilated patients.Low molecular weight heparin appears to be associated with good prognosis in COVID-19 patients and has the ability to reduce coagulation and inflammation markers.Although UFH has been used for several years, it does have practical issues, mainly with respect to the need for frequent monitoring using the activated partial thromboplastin times (aPTT).COVID-19-associated coagulopathy is common in patients with COVID-19, causing high rates of thrombotic complications that increase the morbidity and mortality.Tang et al. recently reported that (Journal of Thrombosis and Haemostasis), in COVID-19 infections caused by the novel coronavirus (SARS-CoV-2), heparin anticoagulant therapy lowers the mortality rate in patients who present with markedly elevated concentrations of D-dimer 1).The Scientific and Standardisation Committee (SSC) on disseminated intravascular coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH) is to be commended for the rapid publication of guidance for clinicians worldwide to assist in management of the coagulopathy widely reported to be associated with severe COVID-19 infection.", "title_summ": "Current Perspectives of Anticoagulation in Patients with COVID-19.[Isoflavones have therapeutic efficacy inoestrogen deficiency].[Dealing with COVID-19-associated coagulopathy].Thrombosis and Thromboembolism Related to COVID\u201019 A clarion call for obtaining solid estimates from large\u2010scale multicenter dataAnticoagulant and antiarrhythmic effects of heparin in the treatment of COVID\u201019 patientsWhat do monitoring platelet counts in COVID\u201019 teach us?Prevalence of Venous Thromboembolism in Critically Ill Patients with COVID\u201019Coagulopathy and Plausible Benefits of Anticoagulation Among COVID-19 PatientsForum article: The protective rather than prothrombotic fibrinogen in COVID\u201019 and other inflammatory statesDynamics of coagulopathy in patients with different COVID-19 severityPathological evidence of pulmonary thrombotic phenomena in severe COVID\u201019Impact of the COVID\u201019 pandemic on therapeutic choices in thrombosis\u2010hemostasisThromboembolic events and apparent heparin resistance in patients infected with SARS\u2010CoV\u20102Heparin \u2013 an old drug with multiple potential targets in Covid\u201019 therapyThe unique characteristics of COVID-19 coagulopathyClinical differentiation of anticoagulant and non\u2010anticoagulant properties of heparinAnticoagulation with Argatroban in patients with acute antithrombin deficiency in severe COVID \u201019Venous Thromboembolism in COVID-19: Towards an Ideal Approach to Thromboprophylaxis, Screening, and TreatmentCoagulopathie associ\u00e9e au COVID-19: les \u00e9l\u00e9ments essentiels pour l\u2019anesth\u00e9siste-r\u00e9animateurType and dose of heparin in COVID-19.Coagulopathy in COVID-19.Potential of Heparin and Nafamostat Combination Therapy for COVID-19.The versatile heparin in COVID-19.COVID-19 Experience in Hemodialysis Patients: A Cue for Therapeutic Heparin-Based Strategies?RE: ISTH interim guidance to recognition and management of coagulopathy in COVID-19.Specific coagulation markers may provide more therapeutic targets in COVID-19 patients receiving prophylactic anticoagulant.", "title_abstract_phrases": "Hospitalized COVID-19 patients should be placed on thromboprophylaxis with the option of full-therapeutic anticoagulation or tissue plasminogen activator (tPA) in high risk or mechanically ventilated patients.Dynamics of coagulopathy in patients with different COVID-19 severityWith the progress of COVID-19 studies, it became evident that SARS-CoV-2 infection is often associated with thrombotic complications.The Scientific and Standardisation Committee (SSC) on disseminated intravascular coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH) is to be commended for the rapid publication of guidance for clinicians worldwide to assist in management of the coagulopathy widely reported to be associated with severe COVID-19 infection.Low molecular weight heparin appears to be associated with good prognosis in COVID-19 patients and has the ability to reduce coagulation and inflammation markers.However, there is a limited amount of data regarding the prevention and management of VTE in severe hospitalized COVID-19 patients."}